Showing results (2701-2710 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|May 27, 2020
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolationPhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Investigational New Drugs|February 10, 2023
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinomaMingzhen Zhou, Sihui Zhu, Chen Xu, et al.
Investigational New Drugs|October 29, 2025
BRPF1 inhibitor GSK6853 inhibits NSCLC cell proliferation via the JAK2/STAT3/CCNA2 axis to induce cell cycle arrestJun Yang, Wei Ji, Lei Liao, et al.
Investigational New Drugs|May 14, 2020
Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature reviewKoichi Ogawa, Hiroyasu Kaneda, Tamaki Kawamoto, et al.
Investigational New Drugs|June 24, 2020
Correction to: The old CEACAMs find their new role in tumor immunotherapyZi-Wen Han, Zhi-Wu Lyv, Bin Cui, et al.
Investigational New Drugs|August 28, 2021
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumorsYannis Metaxas, Carmen Kahatt, Vicente Alfaro, et al.
Investigational New Drugs|August 31, 2021
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinomaDaniel H Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, et al.
Investigational New Drugs|December 1, 1988
A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group StudyE A Eisenhauer, W K Evans, N Murray, et al.
Investigational New Drugs|September 20, 2025
Rucaparib induces mitochondrial fragmentation and apoptosis in prostate cancer cells by targeting Drp1Xiaodong Lu, Yishu Lin, Hao Tang, et al.
Investigational New Drugs|August 4, 2025
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemiaJulie Vrevin, Mélanie Lambert, Marine Andrique, et al.
Pageof 372